Streptococcal infection
diseaseOn this page
Also known as infection, streptococcalinfections, streptococcalStreptococcus caused disease or disorderStreptococcus disease or disorderStreptococcus infectious disease
Summary
Streptococcal infection (MONDO:0021680) is a disease (an umbrella term covering 8 Mondo subtypes) with 1 GWAS associations across 6 studies and 90 clinical trials. Top therapeutic interventions include streptococcus pneumoniae polysaccharide conjugated to corynebacterium diphtheriae crm197, rotavirus, live attenuated, and amoxicillin. A subtype of gram-positive bacterial infections — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Umbrella term: 8 Mondo subtypes
- GWAS associations: 1
- Clinical trials: 90
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | streptococcal infection |
| Mondo ID | MONDO:0021680 |
| EFO | EFO:1001476 |
| MeSH | D013290 |
| NCIT | C87062 |
| SNOMED CT | 85769006 |
| UMLS | C0038395 |
| MedGen | 20963 |
| Is cancer (heuristic) | no |
Also known as: infection, streptococcal · infections, streptococcal · streptococcal infection · Streptococcus caused disease or disorder · Streptococcus disease or disorder · Streptococcus infectious disease
Data availability: 1 GWAS association (6 studies).
Disease family
This is a subtype of gram-positive bacterial infections. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › gram-positive bacterial infections › streptococcal infection
Related subtypes (5): Erysipelothrix infectious disease, Actinomycetales infectious disease, Bacillaceae infectious disease, Clostridium infectious disease, infection caused by Bifidobacterium
Subtypes (8): erysipelas, streptococcal meningitis, impetigo, pneumococcal infection, scarlet fever, streptococcal toxic-shock syndrome, streptococcal sore throat, group B streptococcal infection
Genetics & variants
GWAS landscape
1 GWAS associations across 6 studies. Top hits map to 0 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| rs75866187 | 1e-07 | LINC02183 - CRNDE | ? |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90477039 | Verma A | 2024 | 3,365 | 440,508 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90435520 | Zhou W | 2018 | 1,644 | 393,897 | Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. |
| GCST90477038 | Verma A | 2024 | 826 | 119,035 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90480960 | Verma A | 2024 | 826 | 119,035 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90481428 | Verma A | 2024 | 420 | 58,504 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90651873 | Liu TY | 2025 | 148 | 213,110 | Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 0 |
| Tier 2: splice/UTR | 0 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 1 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 0 |
| low_freq (0.01-0.05) | 0 |
| rare (<0.01) | 0 |
| unknown | 1 |
Functional consequences
| Consequence | Count |
|---|---|
| non_coding_transcript_exon_variant | 1 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| rs75866187 | 16 | 54633237 | A>C | non_coding_transcript_exon_variant | LINC02183 - CRNDE | 1e-07 | Tier 4: intronic/intergenic |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
0 approved, 4 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Acetaminophen | Phase 3 (in late-stage trials) |
| HAEMOPHILUS INFLUENZAE TYPE B STRAIN 20752 CAPSULAR POLYSACCHARIDE TETANUS TOXOID CONJUGATE ANTIGEN | Phase 3 (in late-stage trials) |
| Hepatitis B Virus Hbsag Surface Protein Antigen | Phase 3 (in late-stage trials) |
| Hepatitis B Virus Vaccine Inactivated | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Pertussis Vaccine.
Clinical trials & evidence
Clinical trials
Clinical trials: 90.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE3 | 40 |
| Not specified | 19 |
| PHASE2 | 15 |
| PHASE1 | 10 |
| PHASE4 | 4 |
| PHASE1/PHASE2 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00001658 | PHASE4 | COMPLETED | Amoxicillin for the Treatment of Pediatric Autoimmune Disorders Associated With Streptococcal Infections |
| NCT00261742 | PHASE4 | TERMINATED | Comparative Trial of Oral Penicillin Versus Cefuroxim for Treatment of Perianal Streptococcal Dermatitis |
| NCT01235949 | PHASE4 | COMPLETED | Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A and Prophylactic Antipyretic Treatment |
| NCT02899702 | PHASE4 | WITHDRAWN | Effectiveness of Intravenous Immunoglobulins (IVIG) in Toxic Shock Syndromes in Children |
| NCT07017777 | PHASE3 | RECRUITING | A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks) |
| NCT00307034 | PHASE3 | COMPLETED | Safety & Immunogenicity Study of 10-Valent Pneumococcal Conjugate Vaccine When Administered as a 2-Dose Schedule |
| NCT00307541 | PHASE3 | COMPLETED | Assess the Immunogenicity of GSK Biologicals’ 10-valent Pneumococcal Conjugate Vaccine |
| NCT00307554 | PHASE3 | COMPLETED | A Lot-to-lot Consistency (3 Lots of GSK Biologicals’ 10-valent Pneumococcal Conjugate Vaccine) & Non-inferiority Study |
| NCT00333450 | PHASE3 | COMPLETED | Immune Memory Evaluation in Children Following a Primary Vaccination With Pneumococcal Conjugate Vaccines. |
| NCT00334334 | PHASE3 | COMPLETED | Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals’ 10-valent Pneumococcal Conjugate Vaccine. |
| NCT00344318 | PHASE3 | COMPLETED | Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals’ 10-valent Pneumococcal Conjugate Vaccine |
| NCT00345358 | PHASE3 | COMPLETED | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals’ 10-valent Pneumococcal Conjugate Vaccine |
| NCT00370227 | PHASE3 | COMPLETED | Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals’ 10-valent Pneumococcal Conjugate Vaccine |
| NCT00370396 | PHASE3 | COMPLETED | Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals’ 10-valent Pneumococcal Conjugate Vaccine. |
| NCT00390910 | PHASE3 | COMPLETED | Study to Evaluate the Safety and Immunogenicity of a 10-valent Pneumococcal Conjugate Vaccine in Preterm Infants |
| NCT00466947 | PHASE3 | COMPLETED | COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate Vaccine |
| NCT00489554 | PHASE3 | COMPLETED | Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 12wks of Age |
| NCT00496015 | PHASE3 | COMPLETED | Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Conjugate Vaccine GSK1024850A |
| NCT00547248 | PHASE3 | COMPLETED | Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines |
| NCT00609492 | PHASE3 | COMPLETED | Evaluate Safety and Immunogenicity of a Booster Dose of Pneumococcal Conjugate Vaccine in Preterm Born Infants. |
| NCT00624819 | PHASE3 | COMPLETED | Assessment of Antibody Persistence in Children Previously Vaccinated With Pneumococcal Conjugate Vaccine |
| NCT00652951 | PHASE3 | COMPLETED | Co-administration of Pneumococcal Conjugate Vaccine With DTPa-IPV-Hib Versus Co-administration With DTPa-HBV-IPV/Hib |
| NCT00678301 | PHASE3 | COMPLETED | Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A, Zilbrix™ Hib and Polio Sabin™ |
| NCT00680914 | PHASE3 | COMPLETED | Primary Vaccination Course in Children Receiving Pneumococcal Conjugate Vaccine GSK 1024850A or Prevenar™ and Hiberix™ |
| NCT00792909 | PHASE3 | COMPLETED | Vaccination Course in Primed Children and Age-matched Unprimed Children With Pneumococcal Vaccine GSK1024850A |
| NCT00808444 | PHASE3 | COMPLETED | Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6-12wks of Age |
| NCT00814710 | PHASE3 | COMPLETED | Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of Age |
| NCT00829010 | PHASE3 | COMPLETED | Primary and Booster Vaccination Study With a Pneumococcal Vaccine in HIV Infected, HIV Exposed Uninfected and HIV Uninfected Children 6 to 10 Weeks of Age. |
| NCT00839254 | PHASE3 | COMPLETED | Impact on Carriage, Acute Otitis Media, Immuno & Safety of GSK Biologicals’ Pneumococcal Conjugate Vaccine 1024850A |
| NCT00861380 | PHASE3 | COMPLETED | Evaluation of Effectiveness of GSK Biologicals’ Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease |
| NCT00907777 | PHASE3 | COMPLETED | Vaccination With GSK 1024850A in Children Primed With GSK 1024850A & Boosted With Pneumovax 23™ |
| NCT00911144 | PHASE3 | COMPLETED | Booster Vaccination Study With a Pneumococcal Vaccine in Children Primed With the Same Vaccine |
| NCT00950833 | PHASE3 | COMPLETED | Long-term Follow-up Study of Children Previously Primed With GSK Pneumococcal Vaccine (GSK1024850A) and of Unprimed Children |
| NCT00985465 | PHASE3 | COMPLETED | Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Mali |
| NCT01027845 | PHASE3 | COMPLETED | Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A in Healthy Japanese Children |
| NCT01030822 | PHASE3 | COMPLETED | Booster and Catch-up Vaccination With Vaccine GSK1024850A |
| NCT01119625 | PHASE3 | COMPLETED | Immunological Persistence After Priming With GSK1024850A Vaccine and Safety& Immunogenicity After Booster Dose |
| NCT01153841 | PHASE3 | COMPLETED | Primary Vaccination Study With GSK Biologicals’ Pneumococcal Vaccine in Healthy Infants in Vietnam |
| NCT01153893 | PHASE3 | COMPLETED | Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Nigeria |
| NCT01175083 | PHASE3 | COMPLETED | Immunization of Children Between 8 Weeks and 2 Years of Age With GSK Pneumococcal Vaccine GSK1024850A |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE CRM197 | 4 | 7 |
| ROTAVIRUS, LIVE ATTENUATED | 4 | 3 |
| AMOXICILLIN | 4 | 2 |
| ACETAMINOPHEN | 4 | 1 |
| ALBUMIN HUMAN | 4 | 1 |
| IBUPROFEN | 4 | 1 |
| LINEZOLID | 4 | 1 |
| ORITAVANCIN | 4 | 1 |
| PENICILLIN G | 4 | 1 |
| PENTETIC ACID | 4 | 1 |
| TECHNETIUM TC 99M PENTETATE | 4 | 1 |
| HAEMOPHILUS INFLUENZAE TYPE B STRAIN 20752 CAPSULAR POLYSACCHARIDE TETANUS TOXOID CONJUGATE ANTIGEN | 3 | 3 |
| PROPOLIS WAX | 3 | 1 |
| CEFTOBIPROLE | 2 | 4 |
| RADEZOLID | 2 | 1 |
| CHEMBL5592090 | 0 | 1 |
| CHEMBL4468082 | 0 | 1 |
| CHEMBL193646 | 0 | 1 |
Related Atlas pages
- Drugs: STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE CRM197, Rotavirus, Live Attenuated, Amoxicillin, Acetaminophen, Albumin Human, Ibuprofen, Linezolid, Oritavancin, Penicillin G, Pentetic Acid, TECHNETIUM TC 99M PENTETATE, HAEMOPHILUS INFLUENZAE TYPE B STRAIN 20752 CAPSULAR POLYSACCHARIDE TETANUS TOXOID CONJUGATE ANTIGEN, Propolis Wax